论文部分内容阅读
80年代Ca~(2+)损伤学说引入脑缺血损害机制后,细胞内Ca~(2+)超载已被公认为缺血神经细胞损伤、死亡的首要危害因素。早期防止Ca~(2+)入侵细胞内被视为是脑缺血防治的关键措施。1985年,德国拜耳药厂首先合成的二氢吡啶类钙拮抗剂尼莫地平(nimodi-pine),以尼莫通(nimotop)商品名在德国上市。因其具有分子量小、脂溶性高、能通过血脑屏障等特点,对脑血管起选择性作用,使脑血管扩张,
Ca ~ (2+) damage in the 1980s introduced the mechanism of cerebral ischemia, intracellular Ca ~ (2+) overload has been recognized as the primary injury of ischemic neuronal damage and death. Early prevention of Ca ~ (2+) invasion into cells is considered as a key measure for prevention and treatment of cerebral ischemia. In 1985, the first synthetic dihydropyridine calcium antagonist nimodi-pine from Bayer AG in Germany was marketed in Germany under the nimotop brand name. Because of its molecular weight is small, high fat-soluble, through the blood-brain barrier and other characteristics of cerebrovascular play a selective role in the expansion of cerebrovascular,